newsfilter
← Latest News
GlobeNewswire·

NorthStrive Biosciences Announces The Filing of Two U.S. Patent Applications Targeting Microgravity-Induced Muscle Loss During Long-Duration Spaceflight

ELAB
  • NorthStrive Biosciences, a subsidiary of PMGC Holdings (NASDAQ: ELAB), filed two new U.S. patent applications (Nos. 19/774,556 for EL-22 & 19/774,575 for EL-32) to protect the use of its lead assets for preserving lean muscle mass in humans exposed to microgravity.
  • The filings extend the intellectual property portfolio for EL-22 & EL-32 into spaceflight-associated muscle atrophy, complementing existing terrestrial applications for obesity-related weight loss & animal health.
  • EL-22 targets myostatin, while EL-32 targets both myostatin & activin A, proteins that negatively regulate skeletal muscle growth.
  • The new applications claim pharmaceutical compositions including myo-2 peptides, multimers, fusion proteins, & engineered probiotics using lactic acid bacteria like Lactobacillus paracasei.
  • Claims cover specific microgravity-exposed patient populations, various delivery forms (oral, nasal, injection, topical), dosing ranges, & combination therapies with apelin or ursolic acid.
  • NorthStrive aims to address the lack of approved pharmacologic therapies for muscle loss caused by microgravity, proposing an orally deliverable approach suited for the mass & volume constraints of spaceflight.
  • The strategy involves broadening the patent estate across multiple patient populations & end markets rather than limiting protection to a single indication.
  • Neither EL-22 nor EL-32 has been approved by the FDA, nor have they been evaluated in humans specifically for muscle loss caused by microgravity exposure.
  • NorthStrive is not currently part of any agreement, contract, or program with NASA, other government space agencies, or commercial space operators regarding these assets.
  • The company states that these are preclinical candidates & the filing of patent applications does not assure that a patent will issue or that the products will be successfully developed or commercialized.